OFD Biopharma

Executive Summary

OFD Biopharma is a specialized contract development and manufacturing organization (CDMO) based in San Diego, focused exclusively on advanced lyophilization (freeze-drying) services for the pharmaceutical and biotech industries. Founded in 2016, the company leverages proprietary technologies to stabilize and preserve sensitive biologics, APIs, and other compounds, primarily in bulk ‘outside the vial’ formats. Its services support a wide range of applications, from small molecules to complex cell and gene therapies, serving clients in biologics, oncology, and immunology. By addressing the critical need for stable, long-lasting formulations, OFD Biopharma positions itself as a niche partner for biopharma companies seeking to extend product shelf life and enable novel delivery methods. As a private, non-venture-backed CDMO, OFD Biopharma operates in a growing market driven by the increasing complexity of biologic drugs and the demand for robust formulation technologies. The company’s focus on bulk lyophilization offers scalability and cost advantages for clients developing high-value therapies. While financial data and specific growth metrics are not publicly available, its presence in the competitive San Diego biotech hub and specialization in a technically demanding area suggest steady demand. The company’s future trajectory depends on its ability to expand capacity, form strategic partnerships, and maintain high quality standards. With the biopharma industry’s continued shift toward biologics and advanced therapies, OFD Biopharma’s services are well-positioned to capture market share.

Upcoming Catalysts (preview)

• TBDAnnouncement of new facility expansion or capacity upgrade65% success
• TBDSigning of a major long-term supply contract with a top biopharma company50% success
• TBDLaunch of a novel lyophilization service for cell and gene therapies45% success